INCY
INCYTE CORP
NASDAQ · Healthcare · Biotechnology · US
$113.25
+0.16%Oct 18, 2026, 22:05 UTC
INCYTE CORP announced that it will present oncology data at the European Society for Medical Oncology Congress 2026.
Source:Oct 8, 2026, 12:00 UTC
INCYTE CORP announced that it will report its third-quarter 2026 financial results.
Source:Oct 2, 2026, 12:07 UTC
Celcuity Inc. appointed David W. Gryska as a director effective October 1, 2026, with an annual base salary of $70,000 and a pro-rated grant of 893 restricted stock units.
Sep 25, 2026, 23:00 UTC
The U.S. FDA approved Atebrioz (zilurgisertib) for adult and pediatric patients with fibrodysplasia ossificans progressiva, as announced by Mirum Pharmaceuticals and Incyte.
Source:Sep 20, 2026, 20:00 UTC
Specialised Therapeutics expanded its existing partnership with Incyte to include ruxolitinib cream (Opzelura) in Australia.
Source:Sep 10, 2026, 21:07 UTC
Whitehawk Therapeutics appointed Vijay Iyengar as a Class III director effective September 9, 2026, with an initial stock option award for 76,080 shares.
Aug 24, 2026, 00:00 UTC
Oruka Therapeutics, Inc. appointed Todd Edwards as Chief Commercial Officer, effective with a base salary of $525,000, a target bonus of 40% of annual base salary, a signing bonus of $200,000, and equity grants including a stock option for 20,000 shares and restricted stock units for 100,000 shares of Oruka common stock.
Jul 29, 2026, 10:00 UTC
Incyte's Opzelura (ruxolitinib) cream received EU approval as the first steroid-free topical JAK inhibitor for adults with moderate atopic dermatitis.
Source:Jul 28, 2026, 13:00 UTC
Incyte Corp settled a lawsuit with the U.S. government over Medicaid rebates tied to eczema cream Opzelura.
Source:Jul 28, 2026, 11:10 UTC
Incyte reported its Q2 FY2026 financial results for the period April-June 2026, with revenue up 37.7% to $1.67403 billion, operating profit up 31.6% to $697.89 million, and diluted EPS of $2.81.
Jul 27, 2026, 09:26 UTC
Incyte announced positive Phase III trial results for Fadeucravacitinib (ICP-488) in moderate-to-severe plaque psoriasis, meeting the primary endpoint.
Source:Jul 21, 2026, 15:40 UTC
Halozyme Therapeutics grants Incyte Corporation rights to its ENHANZE drug delivery technology for developing subcutaneous formulations of cancer therapies.
Source:Jul 3, 2026, 15:58 UTC
Incyte acquired a therapeutics firm focused on bleeding disorders to expand its hematology business.
Source:Jul 3, 2026, 15:58 UTC
Incyte reported first-quarter fiscal 2026 earnings with $1.27 billion in quarterly revenue (21% year-over-year gain), led by Jakafi ($758 million) and Opzelura ($143 million), and net sales of $1.1 billion (20% rise).
Source:Jun 19, 2026, 06:00 UTC
Incyte Japan received approval for Minjuvi (tafasitamab) in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Source:Jun 14, 2026, 20:35 UTC
The U.S. FDA accepted the New Drug Application for zilurgisertib in fibrodysplasia ossificans progressiva under Priority Review.
Jun 5, 2026, 00:00 UTC
AbCellera Biologics Inc. appointed Victor Sandor as a Director, effective June 1, 2026.
May 30, 2026, 13:00 UTC
Incyte announced positive results from the pivotal Phase 3 frontMIND trial of tafasitamab combination therapy, showing significant prolongation of progression-free survival in patients with relapsed or refractory follicular lymphoma.
Source: